Dr. Anthony Polverino joined BrainStorm’s board in February 2018. He has extensive product development and commercialization experience in the biotechnology industry. He is currently Executive Vice President, Early Development and Chief Scientific Officer at Zymeworks Inc. Prior to joining Zymeworks, Dr. Polverino was interim Chief Scientific Officer at Kite, which was acquired by Gilead for $11.9B. Kite developed axicabtagene ciloleucel (Yescarta®), a chimeric antigen receptor (CAR)-T cell immunotherapy which was recently approved in the United States for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Prior to joining Kite, Dr. Polverino was at Amgen for 20 years, where he held various positions of increasing responsibility. As a Director in the Oncology Department and Executive Director and Head of the Therapeutic Innovation Unit, he led the discovery and development of multiple IND programs.

Dr. Polverino earned his PhD from Flinders University as well as a BSc from Adelaide University.